A PYMNTS Company

Hoping for EU approval of Synthes acquisition, J&J will sell trauma unit to Biomet

 |  April 4, 2012

Johnson & Johnson announced on Tuesday that it will divest the trauma segment of DePuy Orthopaedics (its medical device division) in hopes of winning EU approval for its acquisition of Synthes. The asset will be sold to Biomet for $280 million.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    Full content: Philadelphia Inquirer

     

    Related contentAnalyzing Medical Device Mergers